1/ Should we give as many people one dose of the Pfizer and Moderna vaccines as possible? Or half as many people two doses of vaccine? It’s a data-free zone.
2/ Here’s the Pfizer COVID vaccine clinical trial data. Study participants got their 2nd dose at 21 days. We only have data on how well one dose of the Pfizer vaccine was at protecting against COVID during that 21 day / 3 week period after the first dose. nejm.org/doi/full/10.10…
3/ We don’t know how good or how long that protection would last if someone did NOT get that 2nd dose at 21 days.
4/ Here’s the Moderna COVID vaccine clinical trial data. Study participants got 2nd dose after 28 days. So we only have data on how well one dose of the Moderna vaccine was at protecting against COVID during that 28 day / 4 week period after the 1st dose. nejm.org/doi/full/10.10…
5/ We don’t know how good or how long that protection would last if someone did not get that 2nd dose of Moderna vaccine at 28 days.
6/ We can’t extrapolate protection during that 21-/28-day period between doses to what would happen if someone did NOT get a 2nd dose until months later (or at all). We can make educated guesses, but that's hypothesis and conjecture, not science.
7/ Here’s the data on neutralizing antibody titers in study participants receiving the Pfizer vaccine. Note that the titers are much lower after one dose (measured just prior to 2nd dose at 21 days) than after two doses (measured at 28 and 35 days). nejm.org/doi/full/10.10…
8/ Here’s the data on neutralization antibody titers in study participants receiving the Moderna vaccine. Note that the titers are much lower after one dose (measured just prior to 2nd dose on day 29 of the study) than after 2 doses (measured at 43 days). nejm.org/doi/full/10.10…
9/ Here’s data on CD4+ T-cell responses among study participants receiving the Moderna vaccine. nejm.org/doi/suppl/10.1…
10/ Note that T-cell activity was significantly lower after one dose (measured just prior to second dose on day 29 of the study, 28 days after the first dose) than after two doses (measured at 43 days).
11/ The second doses of the Pfizer and Moderna induced higher levels of antibodies and T-cell responses than one dose alone. T-cells are important in generating immunologic memory. The second dose of both vaccines seem to be important in generating stronger and durable immunity.
12/ The CDC has said patients can wait up to 6 weeks between doses. I (& others like @DrPaulOffit) think that’s OK, but I wouldn’t wait much longer than that. The strength of the immune response is weaker after only one dose & we don't know how durable. chop.edu/centers-progra…
13/ Is it possible that delaying the 2nd dose more than 6 weeks could result in greater durability of response? Based on data from the AstraZeneca trial & on the Chinese Sinovac Biotech vaccine, yes. But whether that applies to the Pfizer & Moderna vaccines, we don't know.
14/ There are many things we'd like to know. But we need to design studies and test our hypotheses. Now is the time to do this (like @peterbachmd has argued), before many have been vaccinated and while there's still widespread community transmission. statnews.com/2021/01/04/sto…
15/ We should test different dosing schedules, with longer intervals between doses. We should test hybrid regimens that combine different types of vaccines, like Oxford is doing, alternating doses of the AstraZeneca and Pfizer vaccines. abc.net.au/news/2021-02-0…
16/ And we should monitor carefully whether lower neutralizing antibody activity could create immune pressure for more mutation to occur and more variants to emerge. There could be a very real risk to generating partial, not complete immunity.
17/ This, too, is a hypothesis and needs to be studied.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
2/ The UK B.1.1.7 variant is more contagious and *may* be more virulent. If someone is infected with a more virulent strain, that means their risk of more severe disease and death is higher.
3/ The UK B.1.1.7 variant is definitely more contagious / transmissible / infections, which means that if you're exposed, you're more likely to get infected. That means more cases, which equals more disease, hospitalizations, and death.
1/ “When I say ‘experts’ in air quotes, it sounds like I’m saying I don’t really trust the experts,” @NYGovCuomo said of pandemic policies. “Because I don’t.” nytimes.com/2021/02/01/nyr…
But he does trust lobbyists, big private hospital systems, and paid consultants like Deloitte.
2/ Because we should trust consultants like Deloitte? Who charged the US government $44M to build a dysfunctional IT system to track COVID vaccination? technologyreview.com/2021/01/30/101…
1/ We need to do better on equity in vaccine rollout. But that means (a) we've got to solve the right problem, and (b) we need the people and tools to solve the problem.
2/ Is it access or is it hesitancy that's led to less vaccination among communities of color? How do the demographics of healthcare workers and the residents of long-term care facilities, who had earliest access, compare with those of the same age in the community at large?
3/ Among healthcare workers who had access to vaccination in their workplace (note that home health aides, out-patient healthcare workers, and others may not have had access at work), were the demographics of those getting vaccinated skewed relative to the total population?
1/ Thanks, @UnivisionNews for helping get good information out about the COVID pandemic.
2/ Translation here:
"This came to my attention. For me, this is an erroneous message for the citizens of Mexico and for the players, young people are doing anything and everything. The doctor Celine Gounder, who was assigned by the incoming @WhiteHouse in November,
3/ "...the new @POTUS, she had the opportunity to write to answer us:
'We cannot rely on natural immunity. We have seen reinfections following natural infection. Positive antibody tests demonstrate prior infection, NOT robust, long-term immunity.'
1/ NYC released its data on COVID vaccinations by race today. Among adults 18+, those vaccinated skew whiter. Black and Latinx NYCers are vaccinated at disproportionately lower rates. www1.nyc.gov/site/doh/covid…
2/ Among adults 18-64, those vaccinated again skew whiter. Asians slightly overrepresented (perhaps because many work in healthcare?) Black and Latinx NYCers ages 18-64 are vaccinated at disproportionately lower rates.
3/ Among NYCers 65+, those vaccinated again skew whiter. Asians slightly underrepresented (perhaps less likely than older whites to be long-term care facility residents?) Black and Latinx ages 65+ are vaccinated at disproportionately lower rates.
1/ New COVID variants are emerging:
- B.1.1.7 from the UK: more transmissible, possibly more virulent. Even if not more virulent, more transmissible = more infections, more disease, more hospitalizations, more death.
2/ - 501Y.V2 from South Africa: immune response elicited by both natural infection & vaccines may be blunted with lower neutralizing antibody activity BUT the Pfizer/Moderna vaccines still appear to be effective. We should soon have data on the AstraZeneca and J&J vaccines, too.
3/ P.1 from Brazil: More transmissible like B.1.1.7 variant from UK. Blunted immune response like 501Y.V2 variant from South Africa. washingtonpost.com/world/2021/01/…